Literature DB >> 25943627

Symptomatic males and female carriers in a large Caucasian kindred with XIAP deficiency.

Magdalena Dziadzio1, Sandra Ammann, Claire Canning, Fiona Boyle, Amel Hassan, Cathy Cale, Mamoun Elawad, Berthe Katrine Fiil, Mads Gyrd-Hansen, Ulrich Salzer, Carsten Speckmann, Bodo Grimbacher.   

Abstract

PURPOSE: X-linked inhibitor of apoptosis (XIAP) deficiency caused by mutations in BIRC4 was originally described in male patients with X-linked lymphoproliferative syndrome type 2 (XLP2). Recent observations have highlighted a critical role of XIAP for the regulation of NOD2 signaling and are probably the molecular basis for increasingly recognized further immune dysregulatory symptoms of XIAP deficient patients, such as inflammatory bowel disease (IBD). We describe a large Caucasian family in which IBD and erythema nodosum (EN) also manifested in female carriers of XIAP mutations.
METHODS: Clinical data and laboratory findings including flow cytometric analysis of XIAP protein expression and sequencing of the BIRC4 gene. NOD2 signaling was investigated by determination of TNFα production in monocytes upon L18-MDP stimulation in vitro.
RESULTS: The BIRC4 nonsense mutation p.P225SfsX226 was identified as the genetic cause of XIAP deficiency in our family. Surprisingly, clinical symptoms were not restricted to male patients, but also occurred in several female carriers. The most severely affected carrier demonstrated random X-inactivation, leading to a significant expression of mutated XIAP protein in monocytes, and consequently to impaired NOD2 responses in vitro.
CONCLUSION: Our report provides further evidence that clinical symptoms of XIAP deficiency are not restricted to male patients. Random X-inactivation may be associated with EN and mild IBD also in female carriers of BIRC4 mutations. Analysis of the X-inactivation pattern reflected by XIAP protein expression can identify such carriers and the analysis of NOD2 signaling by flow cytometry can confirm the functional significance. XIAP expression patterns should be investigated in female patients with a family history of EN and/or IBD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25943627     DOI: 10.1007/s10875-015-0166-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  15 in total

1.  XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease.

Authors:  Rebecca A Marsh; Lisa Madden; Brenda J Kitchen; Rajen Mody; Brad McClimon; Michael B Jordan; Jack J Bleesing; Kejian Zhang; Alexandra H Filipovich
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

2.  A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency.

Authors:  S Ammann; R Elling; M Gyrd-Hansen; G Dückers; R Bredius; S O Burns; J D M Edgar; A Worth; H Brandau; K Warnatz; U Zur Stadt; P Hasselblatt; K Schwarz; S Ehl; C Speckmann
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

3.  Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).

Authors:  Jana Pachlopnik Schmid; Danielle Canioni; Despina Moshous; Fabien Touzot; Nizar Mahlaoui; Fabian Hauck; Hirokazu Kanegane; Eduardo Lopez-Granados; Ester Mejstrikova; Isabelle Pellier; Lionel Galicier; Claire Galambrun; Vincent Barlogis; Pierre Bordigoni; Alain Fourmaintraux; Mohamed Hamidou; Alain Dabadie; Françoise Le Deist; Filomeen Haerynck; Marie Ouachée-Chardin; Pierre Rohrlich; Jean-Louis Stephan; Christelle Lenoir; Stéphanie Rigaud; Nathalie Lambert; Michèle Milili; Claudin Schiff; Helen Chapel; Capucine Picard; Geneviève de Saint Basile; Stéphane Blanche; Alain Fischer; Sylvain Latour
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

4.  Clinical and genetic characteristics of XIAP deficiency in Japan.

Authors:  Xi Yang; Hirokazu Kanegane; Naonori Nishida; Toshihiko Imamura; Kazuko Hamamoto; Ritsuko Miyashita; Kohsuke Imai; Shigeaki Nonoyama; Kazunori Sanayama; Akiko Yamaide; Fumiyo Kato; Kozo Nagai; Eiichi Ishii; Menno C van Zelm; Sylvain Latour; Xiao-Dong Zhao; Toshio Miyawaki
Journal:  J Clin Immunol       Date:  2012-01-08       Impact factor: 8.317

5.  XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome.

Authors:  Stéphanie Rigaud; Marie-Claude Fondanèche; Nathalie Lambert; Benoit Pasquier; Véronique Mateo; Pauline Soulas; Lionel Galicier; Françoise Le Deist; Frédéric Rieux-Laucat; Patrick Revy; Alain Fischer; Geneviève de Saint Basile; Sylvain Latour
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

6.  XIAP variants in male Crohn's disease.

Authors:  Yvonne Zeissig; Britt-Sabina Petersen; Snezana Milutinovic; Esther Bosse; Gabriele Mayr; Kenneth Peuker; Jelka Hartwig; Andreas Keller; Martina Kohl; Martin W Laass; Susanne Billmann-Born; Heide Brandau; Alfred C Feller; Christoph Röcken; Martin Schrappe; Philip Rosenstiel; John C Reed; Stefan Schreiber; Andre Franke; Sebastian Zeissig
Journal:  Gut       Date:  2014-02-26       Impact factor: 23.059

7.  Flow cytometric measurement of SLAM-associated protein and X-linked inhibitor of apoptosis.

Authors:  Rebecca A Marsh; Jack J Bleesing; Alexandra H Filipovich
Journal:  Methods Mol Biol       Date:  2013

8.  Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers.

Authors:  Claire Aguilar; Christelle Lenoir; Nathalie Lambert; Bernadette Bègue; Nicole Brousse; Danielle Canioni; Dominique Berrebi; Maryline Roy; Stéphane Gérart; Helen Chapel; Tobias Schwerd; Laurent Siproudhis; Michela Schäppi; Ali Al-Ahmari; Masaaki Mori; Akiko Yamaide; Lionel Galicier; Bénédicte Neven; John Routes; Holm H Uhlig; Sibylle Koletzko; Smita Patel; Hirokazu Kanegane; Capucine Picard; Alain Fischer; Nadine Cerf Bensussan; Frank Ruemmele; Jean-Pierre Hugot; Sylvain Latour
Journal:  J Allergy Clin Immunol       Date:  2014-06-15       Impact factor: 10.793

9.  X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis.

Authors:  C Speckmann; K Lehmberg; M H Albert; R B Damgaard; M Fritsch; M Gyrd-Hansen; A Rensing-Ehl; T Vraetz; B Grimbacher; U Salzer; I Fuchs; H Ufheil; B H Belohradsky; A Hassan; C M Cale; M Elawad; B Strahm; S Schibli; M Lauten; M Kohl; J J Meerpohl; B Rodeck; R Kolb; W Eberl; J Soerensen; H von Bernuth; M Lorenz; K Schwarz; U Zur Stadt; S Ehl
Journal:  Clin Immunol       Date:  2013-07-31       Impact factor: 3.969

10.  Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling.

Authors:  Rune Busk Damgaard; Berthe Katrine Fiil; Carsten Speckmann; Monica Yabal; Udo zur Stadt; Simon Bekker-Jensen; Philipp J Jost; Stephan Ehl; Niels Mailand; Mads Gyrd-Hansen
Journal:  EMBO Mol Med       Date:  2013-07-01       Impact factor: 12.137

View more
  11 in total

1.  Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease.

Authors:  Steven M Chirieleison; Rebecca A Marsh; Prathna Kumar; Joseph K Rathkey; George R Dubyak; Derek W Abbott
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

2.  Risk-factors Associated With Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review.

Authors:  Asama Lekbua; Jodie Ouahed; Amy E O'Connell; Stacy A Kahn; Jeffrey D Goldsmith; Toshihiko Imamura; Christine N Duncan; Judith R Kelsen; Elizabeth Worthey; Scott B Snapper; Samir Softic
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-07       Impact factor: 2.839

Review 3.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

Review 4.  Pediatric hemophagocytic lymphohistiocytosis.

Authors:  Scott W Canna; Rebecca A Marsh
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

5.  X-linked Inhibitor of Apoptosis Complicated by Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) and Granulomatous Hepatitis.

Authors:  Cathal L Steele; Matthew Doré; Sandra Ammann; Maurice Loughrey; Angeles Montero; Siobhan O Burns; Emma C Morris; Bobby Gaspar; Kimberly Gilmour; Shahnaz Bibi; Hiba Shendi; Lisa Devlin; Carsten Speckmann; David M Edgar
Journal:  J Clin Immunol       Date:  2016-08-05       Impact factor: 8.317

Review 6.  Primary Immunodeficiencies and Inflammatory Disease: A Growing Genetic Intersection.

Authors:  Nassima Fodil; David Langlais; Philippe Gros
Journal:  Trends Immunol       Date:  2016-01-12       Impact factor: 16.687

Review 7.  How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease.

Authors:  Ole Haagen Nielsen; Eric Charles LaCasse
Journal:  Genet Med       Date:  2016-07-14       Impact factor: 8.822

8.  Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1.

Authors:  Marie E Beckner; Ian F Pollack; Mary L Nordberg; Ronald L Hamilton
Journal:  BBA Clin       Date:  2015-11-10

9.  Eosinophilic colitis in a boy with a novel XIAP mutation: a case report.

Authors:  Jiamei Tang; Xiaoying Zhou; Lan Wang; Guorui Hu; Bixia Zheng; Chunli Wang; Yan Lu; Yu Jin; Hongmei Guo; Zhifeng Liu
Journal:  BMC Pediatr       Date:  2020-04-18       Impact factor: 2.125

Review 10.  Evolution of Our Understanding of XIAP Deficiency.

Authors:  Anne C A Mudde; Claire Booth; Rebecca A Marsh
Journal:  Front Pediatr       Date:  2021-06-17       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.